Loading...
XLON
OXB
Market cap990mUSD
Jul 10, Last price  
611.00GBP
1D
0.16%
1Q
7.95%
Jan 2017
200.25%
Name

Oxford Biomedica PLC

Chart & Performance

D1W1MN
XLON:OXB chart
P/E
—
P/S
4.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.96%
Rev. gr., 5y
13.98%
Revenues
169m
+31.01%
760,0007,219,00018,394,00019,120,00011,153,0007,718,0007,756,0005,375,00013,618,00015,909,00027,776,00037,590,00066,778,00064,060,00087,728,000142,797,000139,989,00089,539,000128,797,000168,741,000
Net income
-30m
L-30.24%
-17,626,000-15,289,000-10,041,000-3,515,000-10,290,000-12,631,000-8,730,000-11,096,000-8,661,000-13,019,000-16,641,000-9,017,0007,541,000-16,066,000-6,245,00019,011,000-39,157,000-157,490,000-43,190,000-30,128,000
CFO
-5m
L-89.23%
-17,128,0004,730,000-18,133,0002,314,000-12,828,000-12,983,000-10,037,000-11,019,000-6,032,000-13,118,000-5,106,0002,979,00012,868,000-3,508,0003,116,00025,455,000-12,615,000-28,517,000-50,628,000-5,452,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
URL
https://www.oxb.com/
IPO date
Nov 15, 1996
Employees
894
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT